Eisai (4523 JT) and Biogen (BIIB) announced Eisai and Biogen announce biologics licence application for subcutaneous formulation of LEQEMBI for treating early Alzheimer's disease was accepted in China

The acceptance of Eisai and Biogen's biologics license application in China for a new formulation of LEQEMBI marks a significant milestone for both companies in the Alzheimer's treatment landscape.

Newsquawk StaffNewswiresPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

Japan's nuclear regulator says no irregularities at Chugoku Electric's (9504 JT) Shimane nuclear power plant following the earthquake

US President Trump is scheduled to deliver remarks at a GOP member retreat at 10:00EST/15:00GMT on Tuesday and will participate in a policy meeting at 14.30EST/19:30GMT on Tuesday

Eisai (4523 JT) and Biogen (BIIB) announced Eisai and Biogen announce biologics licence application for subcutaneous formulation of LEQEMBI for treating early Alzheimer's disease was accepted in China

Hisamitsu Pharmaceutical (4530 JT) founding family seeks USD 2.9bln privatisation of the Co, according to Bloomberg

[MARKET UPDATE] Copper futures extend on their recent rally with CME futures climbing above the USD 6/lb level, while the benchmark LME copper contract rose to a fresh record high north of USD 13,150/ton

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development could enhance their competitive positioning and growth prospects in a key Asian market, reflecting positively on their stock performance and potentially influencing investor sentiment in the biotechnology sector.

Related headlines

The whole workspace, free to try.

Try it free